Radium-223’s Impact on Skeletal Events in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

Publications

1Huang Ya-Ting, 1Chen Li-Yu, 2Chang Yen-Hsiang.

1 Primo Biotechnology Co., Ltd , Taipei, Taiwan.
2Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan.
This study poster was presented at 2025 65th Annual Meeting of the Japanese Society of Nuclear Medicine (JSNM).

Purpose: To evaluate the clinical benefit of Radium-223 (Ra-223) in delaying symptomatic skeletal events (SSEs) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Procedure: A systematic search was conducted in PubMed and Cochrane Library to identify studies on Ra-223 in mCRPC patients with bone metastases up to March 10, 2023. The pooled incidence and time to first SSE were analyzed using random-effects meta-analysis.

Result: A total of 37 studies with 8,103 patients were included. The pooled incidence of SSEs was 19% (95% CI: 15 -25%). Median time to first SSE was 17.14 months (95% CI: 11.98 -23.02). Ra-223 significantly delayed SSE onset compared to placebo. Combination therapy further extended the time to first SSE.

Conclusion: Ra-223 effectively delays SSEs in mCRPC, especially in combination regimens, supporting its clinical utility.

About Primo

Primo collaborates with both domestic and international partners to accelerate progress in precision oncology, leveraging its capabilities in drug development, clinical translation, and GMP manufacturing to support next-generation therapeutics. For more information, please follow Primo Biotech on Facebook and LinkedIn.